The Group's principal activity is developing life-changing therapies in the areas of neuroscience and metabolic disease. It has two lead drug candidates for the treatment of Alzheimer's disease (AD) and type 2 diabetes (T2D).
Alacra Alerts:
Receive alerts on the latest reports on Transition Therapeutics Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
